PHVS Rasio cepet Pharvaris N.V.

Due to Swiss law and the humanitarian status of medicine, Pharvaris N.V. (PHVS) is shielded from geopolitical risks. This chart shows the market price accompanied by the 11.68 indicator. The business focuses on replacing injections with convenient tablets for the therapy of angioedema. Simultaneously, the company treats orphan diseases while implementing closed-loop water supply systems and energy-efficient technologies in its centers to comply with environmental regulations.

A fundamental valuation of Pharvaris N.V. (PHVS) requires an analysis of the company's ability to cover short-term debts without liquidating inventory. The ratio of cash and accounts receivable to liabilities, reflected in the quick ratio, is critical for Pharvaris N.V. (PHVS), as high liquidity serves as the only reliable buffer against potential regulatory rejections or failures in late-stage clinical trials.